ArticleThe journal of nutrition, health & aging2026
Association of baseline and cumulative CHG index with risk of new-onset sarcopenia in middle-aged and older adults.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCHG index, a novel metabolic biomarker calculated from total cholesterol, high-density lipoprotein cholesterol, and fasting blood glucose, is associated with type 2 diabetes and cardiovascular diseases. However, its association with the risk of new-onset sarcopenia in middle-aged and older adults remains unclear.
methodsWe included participants aged ≥50 years from the CHARLS 2011-2012, with follow-up in 2015-2016. Cumulative CHG was derived from measurements in 2011 and 2015. New-onset sarcopenia was diagnosed according to the 2025 AWGS consensus. Multivariable Cox regression and logistic regression were used to examine the associations of baseline and cumulative CHG with new-onset sarcopenia. ROC curves were employed to compare the predictive capability of CHG and TyG.
resultsA total of 5580 participants were included in the baseline analysis. During the 4-year follow-up, 590 (10.6%) participants developed sarcopenia. Compared with the lowest quartile (Q1) of baseline CHG, the highest quartile (Q4) was significantly associated with an increased risk of sarcopenia (HR = 1.287, 95% CI: 1.022-1.619) in the fully adjusted model. K-means clustering categorized 3287 participants into two distinct groups based on cumulative CHG trajectories. Compared with the low-stable group (Cluster 1, n = 1783), the high-declining group (Cluster 2, n = 1504) had a significantly higher risk of new-onset sarcopenia (OR = 1.25, 95% CI: 1.02-1.45). RCS analysis revealed a linear association between baseline CHG and sarcopenia risk. The predictive performance of the baseline and cumulative CHG index was modestly higher than that of the baseline and cumulative TyG index.
conclusionElevated baseline and cumulative CHG indices are independent risk factors for new-onset sarcopenia in middle-aged and older Chinese adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.